CEPI awards $5.2m funding for Nipah virus vaccine research
Posted: 13 October 2022 | Victoria Rees (Drug Target Review) | No comments yet
A Boston University researcher has been granted funding for the development pre-clinical models to test potential Nipah virus vaccines.
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced that it has granted $5.2 million in funding to Dr Anthony Griffiths, associate professor of microbiology at Boston University (BU), US to support the development of vaccines against the Nipah virus.
Griffiths and his team of scientists are working to understand the biology of emerging and re-emerging viruses and to deploy their knowledge to support the development of vaccines and therapies.
Since 2017, CEPI has invested up to $100 million in four promising Nipah vaccine candidates, being developed by teams across academia and industry. CEPI’s overarching goal, as part of its plan to reduce or even eliminate future epidemics and pandemics threats, is to develop a licenced Nipah vaccine or additional medical countermeasure.
Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing
This report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
Inside the report:
- Advance discovery through miniaturised, high-throughput and animal-free systems
- Integrate AI, robotics and analytics to speed decision-making
- Streamline cell therapy and bioprocess QC for scale and compliance
- And more!
This report unlocks perspectives that show how automation is changing the scale and quality of discovery. The result is faster insight, stronger data and better science – access your free copy today
The new BU funding will be pivotal to supporting this ambition. Through this new partnership with CEPI, Griffiths will provide CEPI-supported Nipah vaccine developers with pre-clinical models to test their vaccine candidates that will allow vaccine developers to rapidly assess their candidates. It also allows CEPI and potential future vaccine regulators to be sure that the vaccine has been assessed in its early stages under rigorous quality standards.
“Nipah is an emerging zoonotic virus with a high fatality rate that is associated with sporadic outbreaks. However, this virus is thought to be a major concern for a future pandemic,” concluded Griffiths.
COMMENT: The best protection from COVID-19 will come from intranasally-delivered vaccines, due to the effectiveness of mucosal IgA antibodies, say researchers from the University at Buffalo…
Related topics
Funding, Immunology, In Vivo, Translational Science, Vaccine
Related conditions
Nipah virus
Related organisations
Boston University (BU), Coalition for Epidemic Preparedness Innovations (CEPI)
Related people
Dr Anthony Griffiths
